[1]孙杰,胡涛.m6A修饰在胶质瘤中作用的研究进展[J].中国临床神经外科杂志,2024,29(05):304-307312.[doi:10.13798/j.issn.1009-153X.2024.05.014]
 SUN Jie,HU Tao.Research progress on the role of m6A modification in glioma[J].,2024,29(05):304-307312.[doi:10.13798/j.issn.1009-153X.2024.05.014]
点击复制

m6A修饰在胶质瘤中作用的研究进展()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年05期
页码:
304-307312
栏目:
综述
出版日期:
2024-05-30

文章信息/Info

Title:
Research progress on the role of m6A modification in glioma
文章编号:
1009-153X(2024)05-0304-04
作者:
孙杰胡涛
030001太原,山西医科大学第五临床医学院(孙杰);030001太原,山西医科大学附属人民医院神经外科(胡涛)
Author(s):
SUN Jie1 HU Tao2
1. The Fifth Clinical College of Shanxi Medical University, Taiyuan 030001, China; 2. Department of Neurosurgery, Affiliated People's Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
胶质瘤N6-甲基腺嘌呤(m6A)修饰发病机制预后
Keywords:
Glioma N6-methyladenosine (m6A) modification Pathogenesis Prognosis
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2024.05.014
文献标志码:
A
摘要:
胶质瘤是中枢神经系统最常见的恶性肿瘤,即使采用综合治疗方案(手术联合术后放/化疗),效果仍不理想,预后很差。所以,了解胶质瘤的病理生理机制极为重要。N6-甲基腺嘌呤(m6A)修饰是RNA修饰中最常见的RNA转录后修饰方式,几乎在所有的生物过程中起重要作用。m6A是中枢神经系统中高丰度的重要转录组标记,在神经系统发育中起至关重要的作用。近年来,研究表明m6A修饰与胶质瘤特别是胶质母细胞瘤的发生、发展有关,但是目前关于m6A修饰在胶质瘤中的作用研究还处于起步阶段。本文就m6A修饰在胶质瘤发生、发展的作用以及在治疗、预后评估中的价值的研究进展进行综述。
Abstract:
Glioma is the most common malignant tumor in the central nervous system, and even with combined treatment regimens (surgery followed by postoperative radiation/chemotherapy), the outcomes are not satisfactory, with poor prognosis. Therefore, understanding the pathophysiological mechanisms of glioma is of great importance. N6-methyladenosine (m6A) modification is the most common form of RNA post-transcriptional modification, playing an important role in virtually all biological processes. m6A is a highly abundant important transcriptomic marker in the central nervous system and plays a crucial role in neural development. Recent studies have shown that m6A modification is associated with the occurrence and development of glioma, especially glioblastoma, but research on the role of m6A modification in glioma is still in the starting stage. This review summarizes the advances in the role of m6A modification in the occurrence, development, treatment, and prognosis assessment of glioma.

参考文献/References:

[1]MEYER KD, SALETORE Y, ZUMBO P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons [J]. Cell, 2012, 149(7): 1635-1646.
[2]WANG J, SHA Y, SUN T. m6A modifications play crucial roles in glial cell development and brain tumorigenesis [J]. Front Oncol, 2021, 11: 611660.
[3]CHANG YZ, CHAI RC, PANG B, et al. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma [J]. Cancer Lett, 2021, 511: 36-46.
[4]ZHU X, YANG H, ZHANG M, et al. YTHDC1-mediated VPS25 regulates cell cycle by targeting JAK-STAT signaling in human glioma cells [J]. Cancer Cell Int, 2021, 21(1): 645.
[5]TAO M, LI X, HE L, et al. Decreased RNA m6A methylation enhances the process of the epithelial mesenchymal transition and vasculogenic mimicry in glioblastoma [J]. Am J Cancer Res, 2022, 12(2): 893-906.
[6]ZEECKI JP, KARAMBIZI D, FAJARDO JE, et al. miRNA-mediated loss of m6A increases nascent translation in glioblastoma [J]. PLoS Genet, 2021, 17(3): e1009086.
[7]ZHANG S, ZHAO S, QI Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner [J]. Mol Ther Nucleic Acids, 2022, 27: 699-717.
[8]WEI C, WANG B, PENG D, et al. Pan-cancer analysis shows that alkbh5 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including gliomas [J]. Front Immunol, 2022, 13: 849592.
[9]LI L, ZHOU M, CHEN B, et al. ALKBH5 promotes cadmium-induced transformation of human bronchial epithelial cells by regulating PTEN expression in an m6A-dependent manner [J]. Ecotoxicol Environ Saf, 2021, 224: 112686.
[10]CHAI RC, CHANG YZ, CHANG X, et al. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma [J]. J Hematol Oncol, 2021, 14(1): 109.
[11]FANG R, CHEN X, ZHANG S, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma [J]. Nat Commun, 2021, 12(1): 177.
[12]YARMISHYN AA, YANG YP, LU KH, et al. Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1 [J]. Cancer Cell Int, 2020, 20(1): 597.
[13]CONG P, WU T, HUANG X, et al. Identification of the role and clinical prognostic value of target genes of m6a rna methylation regulators in glioma [J]. Front Cell Dev Biol, 2021, 9: 709022.
[14]ZHONG C, TAO B, YANG F, et al. Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a [J]. Clin Transl Med, 2021, 11(9): e424.
[15]KOWALSKI-CHAUVEL A, LACORE MG, Arnauduc F, et al. The m6A RNA demethylase ALKBH5 promotes radioresistance and invasion capability of glioma stem cells [J]. Cancers (Basel), 2020, 13(1): 40.
[16]LI F, CHEN S, YU J, et al. Interplay of m6 A and histone modifications contributes to temozolomide resistance in glioblastoma [J]. Clin Transl Med, 2021, 11(9): e553.
[17]LI XD, WANG MJ, ZHENG JL, et al. Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multi-forme cells [J]. Cancer Sci, 2021, 112(11): 4543-4552.
[18]XIAO L, LI X, MU Z, et al. FTO inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma [J]. Cancer Res, 2020, 80(18): 3945-3958.
[19]RADOUL M, LEWIN L, COHEN B, et al. Genetic manipulation of iron biomineralization enhances MR relaxivity in a ferritin-M6A chimeric complex [J]. Sci Rep, 2016, 6: 26550.
[20]GUAN S, HE Y, SU Y, et al. A risk signature consisting of eight m6a methylation regulators predicts the prognosis of glioma [J]. Cell Mol Neurobiol, 2022, 42(8): 2733-2743.
[21]ZHENG J, WANG X, QIU Y, et al. Identification of critical m6A RNA methylation regulators with prognostic value in lower-grade glioma [J]. Biomed Res Int, 2021, 2021: 9959212.
[22]CHAI RC, WU F, WANG QX, et al. m6A RNA methylation regulators contribute to malignant progression and have clinical prognos- tic impact in gliomas [J]. Aging (Albany NY), 2019, 11(4): 1204-1225.
[23]ZHAO WJ, OU GY, LIN WW. Integrative analysis of neuregulin family members-related tumor microenvironment for predicting the prognosis in gliomas [J]. Front Immunol, 2021, 12: 682415.
[24]BAI Z, WANG X, ZHANG Z. Establishment and validation of a 5 m6A RNA methylation regulatory gene prognostic model in low-grade glioma [J]. Front Genet, 2022, 13: 655169.
[25]CHEN Y, GUO Y, LI S, et al. Identification of N6-methyladenosine-related lncRNAs as a prognostic signature in glioma [J]. Front Oncol, 2022, 12: 789283.
[26]NGUYEN QH, NGUYEN T, LE DH. Identification and validation of a novel three hub long noncoding RNAs with m6A modification signature in low-grade gliomas [J]. Front Mol Biosci, 2022, 9: 801931.

相似文献/References:

[1]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
 CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
 XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(05):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
 LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(05):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波 杨宇焦 张 逵 范润金 张 渊 杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
 YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(05):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚 成于思 王 辉 汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
 HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(05):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林 雨 张 恺 李 帅 杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明 徐成仕 王泽芬 曹长军 李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
 DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(05):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生 田道锋 张申起 陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
 PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(05):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯 驰 郭双毅 程龙海 罗 杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
 FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(05):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]

备注/Memo

备注/Memo:
(2022-05-04收稿,2024-01-12修回)
通信作者:胡 涛,Email:namucuoo2000@sina.com
更新日期/Last Update: 2024-05-30